종합적 대사 패널 검사 시장 예측(-2030년) : 검사 유형, 질병, 최종 사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Comprehensive Metabolic Panel Testing Market is accounted for $11.32 billion in 2023 and is expected to reach $23.65 billion by 2030 growing at a CAGR of 11.1% during the forecast period. A diagnostic blood test called a Comprehensive Metabolic Panel (CMP) offers a thorough assessment of a person's metabolic health. It assesses a number of markers linked to blood sugar, electrolyte balance, and organ function. Tests for glucose, electrolytes, and liver, kidney, and protein levels in the blood are commonly included in a CMP. Moreover, this panel helps identify and track diseases like diabetes, liver disease, and kidney dysfunction by providing insightful information about the general health of important organs like the liver and kidneys.

According to International Diabetes Federation (IDF), over 540 million people are suffering from diabetes worldwide, and by 2045 the numbers are expected to cross 780 million marks.

Market Dynamics:

Driver:

Increased frequency of metabolic illnesses

One major factor propelling the market for Comprehensive Metabolic Panel (CMP) testing is the rising prevalence of metabolic disorders worldwide, such as diabetes, obesity, and non-alcoholic fatty liver disease. Additionally, regular metabolic profiling is imperative to facilitate early detection, intervention, and efficient disease management, given the increasing prevalence of lifestyle factors and dietary patterns associated with these conditions.

Restraint:

Low level of education and awareness

Even with the growing focus on preventive healthcare, there is still a significant knowledge gap about the significance of full metabolic panel testing. The lack of awareness among healthcare professionals and the general public regarding the comprehensive range of data these tests offer and their significance in the early identification of illnesses impedes their use. Furthermore, in order to overcome this limitation, focused education campaigns that foster knowledge and proactive participation in metabolic health monitoring are required, aimed at both the general public and healthcare professionals.

Opportunity:

Targeted therapies and personalized medicine

There is a big chance for the market because of the growing emphasis on personalized medicine. The precision of treatment plans can be improved by combining metabolic panel data with individual genetic information as molecular diagnostics and genetic profiling continue to advance. Moreover, this makes it possible to develop targeted therapies that are suited to each patient's particular metabolic profile, enhancing treatment effectiveness and reducing side effects.

Threat:

Pricing pressure and the competitive environment

The CMP testing market is significantly threatened by the industry as well as pricing pressures. A pricing war amongst diagnostic companies could jeopardize the long-term viability of comprehensive metabolic panel testing services due to intense competition. Additionally, laboratories must use cost-cutting strategies, value-added services, and strategic differentiation to survive in this cutthroat market without sacrificing customer satisfaction.

COVID-19 Impact:

There are several ways in which the COVID-19 pandemic has affected the market. A brief drop in routine diagnostic testing, including CMP tests, was initially caused by disruptions in healthcare services, issues with the supply chain, and a change in healthcare priorities toward managing the pandemic. The significance of thorough metabolic assessments in determining the effects of COVID-19 on patients, particularly those with metabolic complications, was acknowledged more as the healthcare sector adjusted to the new normal. Furthermore, point-of-care testing, telemedicine, and digital health solutions have all seen rapid adoption as a result of the pandemic, which has changed the dynamics of the CMP testing market.

The Diabetes segment is expected to be the largest during the forecast period

Due to the fact that diabetes is a chronic condition with a high prevalence, it is expected to hold the largest share of the market. Diabetes is a metabolic disease that affects millions of people worldwide and is typified by elevated blood glucose levels. Moreover, a broad range of goods and services are available in the diabetes management market, such as prescription drugs, glucose monitors, insulin treatments, and lifestyle modifications. Significant investments have been made in research, development, and creative approaches to disease management as a result of the rising prevalence of diabetes, which is fueled by factors like sedentary lifestyles and poor dietary habits.

The Point of care Centers segment is expected to have the highest CAGR during the forecast period

The market's highest CAGR is being seen in the point-of-care centers segment. Point-of-care testing has become increasingly popular because of its ease of use, speed, and capacity to simplify the delivery of healthcare. It is typified by quick diagnostics and real-time results at or close to the patient. These facilities provide a broad range of diagnostic services, with results available in a matter of minutes. These services include blood tests, urinalysis, and other crucial assessments. Additionally, point-of-care center expansion has been driven by the growing emphasis on decentralizing healthcare services, increasing patient accessibility, and shortening diagnosis turnaround times.

Region with largest share:

The market for CMP testing is expected to have the largest share in the North American region. A large patient population with chronic metabolic conditions, a well-established healthcare infrastructure, and a high level of awareness regarding preventive healthcare are some of the factors contributing to the region's dominance. Furthermore, technology developments, the existence of major industry players, and advantageous reimbursement practices have all aided in the expansion of the CMP testing market in North America.

Region with highest CAGR:

The comprehensive metabolic panel (CMP) testing market is expected to grow at the highest CAGR in the Asia-Pacific region. A number of factors are driving the region's growth, such as a quickly growing population, growing healthcare awareness, and an increase in the prevalence of metabolic disorders. The Asia-Pacific region's burgeoning need for comprehensive metabolic panel testing is partly due to improved healthcare infrastructure and the uptake of cutting-edge diagnostic technologies. Moreover, the market in this region is expected to grow at a robust rate due to the increasing prevalence of lifestyle-related diseases and the growing emphasis on early detection and management.

Key players in the market:

Some of the key players in Comprehensive Metabolic Panel Testing market include Charles River Laboratories Inc., Genoptix Inc., Baptist Health Medical Group, ARUP Laboratories, Scion Lab Services LLC, NeoGenomics Laboratories, Inc., Abbott Laboratories, Unipath, Siemens Healthcare GmbH, Nova Medical, CENTOGENE N.V., Quest Diagnostics Incorporated, Cleveland HeartLab, Inc., Sonic Healthcare, TCG Corp. and SYNLAB International GmbH.

Key Developments:

In December 2023, Charles River Laboratories International, Inc. announced an important milestone in their strategic collaboration to manufacture CASGEVY™. CASGEVY is approved in some countries for certain eligible patients. The news follows Charles River's Memphis center of excellence passing back-to-back audits from both the U.S. Food and Drug Administration and the Health Products Regulatory Authority, on behalf of the European Medicines Agency.

In December 2023, Baptist Health Baptist Hospital launched the Inspiration Hall, powered by national leader in hospice and palliative care services, VITAS Healthcare. Located on the first floor near the hospital's imaging center waiting room, the Inspiration Hall is an immersive experience where patients, visitors and hospital team members can submit, read or watch messages of comfort and support that will inspire others in their health journey.

In December 2023, A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union. ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN™, a new gene therapy developed by BioMarin.

Test Types Covered:

• Glucose
• Calcium
• Electrolytes
• Kidney Function Tests
• Liver Function Tests
• Proteins
• Other Test Types

Diseases Covered:

• Diabetes
• Kidney Disease
• Liver Disease
• Other Diseases

End Users Covered:

• Point of Care Centers
• Diagnostic Laboratories
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Comprehensive Metabolic Panel Testing Market, By Test Type

• 5.1 Introduction
• 5.2 Glucose
• 5.3 Calcium
• 5.4 Electrolytes
  • 5.4.1 Sodium
  • 5.4.2 Potassium
  • 5.4.3 Other Electrolytes
• 5.5 Kidney Function Tests
  • 5.5.1 Blood Urea Nitrogen (BUN)
  • 5.5.2 Creatinine
• 5.6 Liver Function Tests
  • 5.6.1 Albumin
  • 5.6.2 Bilirubin
  • 5.6.3 Alkaline Phosphatase
  • 5.6.4 Aspartate Aminotransferase (AST)
  • 5.6.5 Alanine Aminotransferase (ALT)
• 5.7 Proteins
• 5.8 Other Test Types

6 Global Comprehensive Metabolic Panel Testing Market, By Disease

• 6.1 Introduction
• 6.2 Diabetes
• 6.3 Kidney Disease
• 6.4 Liver Disease
• 6.5 Other Diseases

7 Global Comprehensive Metabolic Panel Testing Market, By End User

• 7.1 Introduction
• 7.2 Point of Care Centers
• 7.3 Diagnostic Laboratories
• 7.4 Hospitals
• 7.5 Other End Users

8 Global Comprehensive Metabolic Panel Testing Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Charles River Laboratories Inc.
• 10.2 Genoptix Inc.
• 10.3 Baptist Health Medical Group
• 10.4 ARUP Laboratories
• 10.5 Scion Lab Services LLC
• 10.6 NeoGenomics Laboratories, Inc.
• 10.7 Abbott Laboratories
• 10.8 Unipath
• 10.9 Siemens HealthCare GmbH
• 10.10 Nova Medical
• 10.11 CENTOGENE N.V.
• 10.12 Quest Diagnostics Incorporated
• 10.13 Cleveland HeartLab, Inc.
• 10.14 Sonic HealthCare
• 10.15 TCG Corp.
• 10.16 SYNLAB International GmbH